Vemurafenib

维罗非尼

Report date: 2023/05/06 18:40:36
NMEFirst In Class

Base Information

Drug NameVemurafenib
Drug Alias Name维拉非尼VemurafenibumVermofenib威罗菲尼维莫非尼 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitors
TargetsSerine/threonine-protein kinase B-raf
Therapy Area/IndicationsSolid tumoursErdheim-Chester DiseaseHistiocytosis +[26] 
Global Approved IndicationsMelanoma
Approved Indications in ChinaMelanoma
Original Approved Country/TerritoryUnited States
Original Approved Date2011/08/17
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[53] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoShanghai Kezhou Pharmaceutical Co., Ltd.Chugai Pharmaceutical Co Ltd +[15] 
Inactive CompaniesUtah State UniversityRoche Pharma AgYale University +[6] 
Active IndicationsSolid tumoursErdheim-Chester DiseaseHistiocytosis +[22] 
Inactive IndicationsNeoplasm MetastasisColorectal NeoplasmsMultiple Myeloma +[4] 

Other Information

ATC CodeL01EC01
Related LinksWikipediaDrugBankKEGG